MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Clinical laboratories face challenges with insufficient DNA from formalin-fixed, paraffin-embedded tumors for methylation analysis.
• Existing methods like bisulfite or methylation-sensitive restriction enzymes require substantial DNA input.

Purpose of the Study:

• To develop a sensitive method for DNA methylation profiling and mutation detection in clinical samples.
• To establish a novel assay for analyzing challenging formalin-fixed, paraffin-embedded tumor tissues.

Main Methods:

• Developed MethylMeter assay combining methyl-CpG DNA capture and Coupled Abscription PCR Signaling detection.
• Analyzed gliomas for MGMT methylation, glioma CpG island methylator phenotype, and IDH1 R132H mutation.
• Utilized formalin-fixed and paraffin-embedded tumor tissues.

Main Results:

• MethylMeter achieved a 100% assay success rate for all five biomarkers in formalin-fixed, paraffin-embedded tissues.
• MGMT methylation results correlated with survival and mRNA expression data.
• The MethylMeter-based GliomaSTRAT assay simultaneously grades gliomas and predicts temozolomide response.

Conclusions:

• MethylMeter is a sensitive, quantitative method for multitarget DNA methylation profiling and mutation detection.
• The GliomaSTRAT assay provides clinically valuable information for glioma management.
• This assay enables simultaneous glioma grading and prediction of treatment response.